EMAIL THIS PAGE TO A FRIEND

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[The experience of using the atypical antipsychotic sertindole in psychiatric inpatient clinics in Russia].


PMID 21716249

Abstract

One hundred and fifty psychiatrists from 61 clinics of 30 cities located in 8 regions of the Russian Federation took part in the study. The study included 896 patients treated with sertindole. The duration of illness was from 1 month to 50 years (mean 9,55 ± 8,21), a number of previous relapses varied from 0 to 20 and more (mean 5,79 ± 6,68). Each patient was followed up for 6 weeks. Patient's state was assessed clinically and with the CGI. The statistically significant improvement was seen from the first week of treatment and the percentage of patients with marked mental disorders was constantly decreased from the first to the 6th week. It has been concluded that sertindole is an effective drug for stopping psychotic symptoms in the real practice of treatment of schizophrenic patients. It is well-tolerated and allows to reduce a number of concurrent drugs used for treatment.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

S8072
Sertindole, ≥97.5% (HPLC)
C24H26ClFN4O